https://scholars.lib.ntu.edu.tw/handle/123456789/635377
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | SHANG-JU WU | en_US |
dc.contributor.author | Lin, Chien-Ting | en_US |
dc.contributor.author | Liao, Cheng Hao | en_US |
dc.contributor.author | Lin, Chun-Ming | en_US |
dc.date.accessioned | 2023-09-14T05:07:45Z | - |
dc.date.available | 2023-09-14T05:07:45Z | - |
dc.date.issued | 2023-05 | - |
dc.identifier.issn | 1936-5233 | - |
dc.identifier.uri | https://www.scopus.com/record/display.uri?eid=2-s2.0-85149748638&doi=10.1016%2fj.tranon.2023.101650&origin=inward&txGid=d8e0cff7db05d68479151e3f999d4b9b | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/635377 | - |
dc.description.abstract | Previous studies have explored the use of engineered blinatumomab-secreting autologous αβ T cells for CD19-targeted cancer therapy. To create a more flexible allogeneic delivery system, we utilized γ9δ2 T cells rather than αβ T cells in a similar application. First, we showed that γ9δ2 T cells could serve as effector cells for blinatumomab, and these effector memory cells could survive for at least 7 days after infusion. The genetically modified blinatumomab-secreting γ9δ2 T cells induced significant cytotoxicity in CD19+ tumor cell lines and primary cells from chronic lymphocytic leukemia patients. Of note, blinatumomab-secreting γ9δ2 T cells might also exhibit dual-targeting of CD19 and isopentenyl pyrophosphate, a universal tumor-associated antigen. Furthermore, blinatumomab-secreting γ9δ2 T cells killed CD19-transfected adherent cells, suggesting that the γ9δ2 T cells might be effective for treating solid tumors with appropriate cancer antigens. Together, these results demonstrate the promise of blinatumomab-secreting γ9δ2 T cells as a cancer therapy. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Translational oncology | en_US |
dc.subject | Bispecific antibody; Blinatumomab; CD19-targeting; γ9δ2 T cells | en_US |
dc.title | Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.tranon.2023.101650 | - |
dc.identifier.pmid | 36917873 | - |
dc.identifier.scopus | 2-s2.0-85149748638 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85149748638 | - |
dc.relation.pages | 101650 | en_US |
dc.relation.journalvolume | 31 | en_US |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.orcid | 0000-0002-0772-869X | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。